J1453 Fosaprepitant HCPCS: Reimbursement & Policy

HCPCS Level II code J1453 denotes injection of fosaprepitant, billed per 1 mg unit. Fosaprepitant is an intravenous antiemetic commonly used to prevent chemotherapy-induced nausea and vomiting, making this code important for oncology treatment pathways and facility billing. Nationally, accurate use of this HCPCS code affects drug billing, infusion center workflows, and uptake of guideline-directed supportive care.

Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a compact overview of reimbursement benchmarks and payer coverage trends, clinical context for use of fosaprepitant in antiemetic regimens, and common billing considerations tied to unitization and site-of-service distinctions.

The publication highlights: typical sites of service where J1453 is billed, how unit-based billing for injectable antiemetics is applied, and payer patterns that influence prior authorization and coding practice. It also summarizes applicable modifiers and operational notes for service lines that manage chemotherapy supportive care. Data not provided in the input are called out as unavailable.

Billing Code Overview

HCPCS Level II code J1453 represents the medication fosaprepitant, billed per 1 mg unit for injection. This code is used when administering fosaprepitant as an intravenous antiemetic agent.

Service type: Injection medication administration

Typical site of service: Hospital outpatient infusion centers, oncology clinics, and ambulatory infusion centers

Data not available in the input.

Clinical Context

A 58-year-old female receiving moderately to highly emetogenic chemotherapy for breast cancer presents to the outpatient infusion center for her scheduled antiemetic prophylaxis. Per the oncology regimen, she requires a single intravenous dose of fosaprepitant prior to chemotherapy to prevent acute and delayed chemotherapy-induced nausea and vomiting. Nursing verifies patient identity, reviews allergies and prior infusion reactions, obtains IV access (peripheral or port), and prepares an IV bag with fosaprepitant reconstituted per manufacturer instructions. The medication, billed with J1453 (fosaprepitant, 1 mg), is administered as an IV infusion over the recommended time. Vital signs and infusion site are monitored during and after administration. Documentation includes indication, dose in mg, lot number, route, infusion start and stop times, site of service (typically outpatient hospital infusion center or physician office), and any immediate adverse reactions. Billing uses J1453 with an appropriate modifier when applicable to reflect services such as professional component, reduced services, or outpatient hospital status.

Coding Specifications

Modifier	Description	When to Use
`JW`	Drug amount discarded/not administered	Use when part of a single-use vial dose is discarded after preparation and the discarded amount must be reported per payer rules.

Taxonomy Code	Specialty	Notes
`207Q00000X`	Medical Oncology	Common prescribing and ordering specialty for fosaprepitant.
`207RH0000X`	Hematology/Oncology	Specialists managing chemotherapy regimens using fosaprepitant.
`207L00000X`	Internal Medicine	Hospitalists or internists who may manage inpatient antiemetic needs.
`363LP0800X`	Infusion Therapy	Nurses and infusion specialists administering IV fosaprepitant.
`2084P0800X`	Emergency Medicine	Occasionally administers antiemetics for oncology patients presenting with severe nausea.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`R11.0`	Nausea	Symptom often present in patients who may receive antiemetic prophylaxis or treatment.
`R11.2`	Nausea with vomiting, unspecified	Common presentation prompting antiemetic therapy in oncology patients.
`T88.7XXA`	Unspecified adverse effect of drug, initial encounter	Relevant if patient experiences an adverse reaction to chemotherapy requiring antiemetic management.
`Z79.890`	Long term (current) use of other agents affecting metabolism	May denote ongoing supportive medication regimens in cancer care (contextual).
`C50.919`	Malignant neoplasm of unspecified site of right female breast	Example cancer diagnosis for which moderately to highly emetogenic chemotherapy and fosaprepitant prophylaxis may be used.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Often used to bill the infusion administration time for initial IV antiemetic infusion in an outpatient setting.
`96366`	Intravenous infusion; each additional hour (List separately in addition to code for primary infusion)	Used when infusion time extends beyond the initial hour for prolonged administration or monitoring.
`96413`	Chemotherapy administration, intravenous infusion technique; up to 1 hour, single or initial substance/drug	May be used when fosaprepitant administration is part of a chemotherapy regimen billed under chemotherapy administration codes.
`90471`	Immunization administration (single) (Note: not directly applicable to fosaprepitant)	Data not available in the input.
`99212`	Office or other outpatient visit for the evaluation and management of an established patient, typically 10 minutes	Used when a significant E/M service is provided the same day as the infusion and reported with modifier `25` if applicable.

OpenPayer

Summary & Overview

HCPCS J1453: Fosaprepitant Injection, 1 mg